Bibliography
- Venters HD, Dantzer R, Kelley KW. A new concept in neurodegeneration: TNFalpha is a silencer of survival signals. Trends Neurosci 2000;23(4):175-80
- Hallahan DE, Vokes EE, Rubin SJ, Phase I dose-escalation study of tumor necrosis factor-alpha and concomitant radiation therapy. Cancer J Sci Am 1995;1(3):204-9
- Weichselbaum RR, Kufe D. Translation of the radio- and chemo-inducible TNFerade vector to the treatment of human cancers. Cancer Gene Ther 2009;16(8):609-19
- Weichselbaum RR, Kufe DW, Hellman S, Radiation-induced tumour necrosis factor-alpha expression: clinical application of transcriptional and physical targeting of gene therapy. Lancet Oncol 2002;3(11):665-71
- Bickenbach KA, Veerapong J, Shao MY, Resveratrol is an effective inducer of CArG-driven TNF-alpha gene therapy. Cancer Gene Ther 2008;15(3):133-9
- Yi JY, Jung YJ, Choi SS, Chung E. TNF-alpha downregulates E-cadherin and Sensitizing Response to gamma-irradiation in Caco-2 Cells. Cancer Res Treat 2009;41(3):164-70
- MacGill RS, Davis TA, Macko J, Local gene delivery of tumor necrosis factor alpha can impact primary tumor growth and metastases through a host-mediated response. Clin Exp Metastasis 2007;24(7):521-31
- Chang KJ, Lee JG, Holcombe RF, Endoscopic ultrasound delivery of an antitumor agent to treat a case of pancreatic cancer. Nat Clin Pract Gastroenterol Hepatol 2008;5(2):107-11
- Senzer N, Mani S, Rosemurgy A, TNFeradeTM biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors. J Clin Oncol 2004;22(4):592-601
- Senzer N, Hanna N, Chung T, Completion of dose escalation component of phase II TNFeradeTM combined with chemoradiation in the treatment of locally advanced pancreatic cancer (LAPC). Presented at ASCO GI; 2005
- Chadha MK, Litwin A, Levea C, Surgical resection after TNFeradeTM therapy for locally advanced pancreatic cancer. JOP 2009;10(5):535-8
- Posner M, Chang K, Rosemurgy A, Multi-center phase 2/3, randomized, controlled clinical trial using TNFeradeTM gene delivery combined with chemoradiation in patients with locally advanced pancreatic cancer (LAPC). Abstract Presented at ASCO; 2007
- Chang K, Fisher W, Kenady D, Multi-center randomized controlled phase III clinical trial using TNFeradeTM with chemoradiation in patients with locally advanced pancreatic cancer: interim analysis of overall survival. Abstract Presented at ASCO; 2009
- Mundt AJ, Vijayakumar S, Nemunaitis J, A Phase I trial of TNFeradeTM biologic in patients with soft tissue sarcoma in the extremities. Clin Cancer Res 2004;10(17):5747-53
- Pawlik TM, Ahuja N, Herman JM. The role of radiation in retroperitoneal sarcomas: a surgical perspective. Curr Opin Oncol 2007;19(4):359-66
- Senzer N, Swisher s, Reid T, Long-term outcome in esophageal cancer after endoscopically delivered intratumoral (IT) injections of TNFeradeTM with neoadjuvant chemoradiotherapy (CRT). Abstract Presented at ASCO; 2006
- Chang KJ, Senzer NN, Soetikno R, Long-term survival analysis of a multicenter clinical trial using endoscopy (END) and endoscopic ultrasound (EUS)-guided fine needle injection (FNI) of antitumor agent (TNFerade Biologic [TNF]) in patients with locally advanced esophageal cancer. Abstract presented at ASCO GI; 2010
- Gunderson LL. Gastric cancer: patterns of relapse after surgical resection Semin Radiat Oncol 2002;12(2):150-61
- Landry J, Tepper JE, Wood WC, Patterns of failure following curative resection of gastric carcinoma. Int J Radiat Oncol Biol Phys 1990;19(6):1357-62
- Vokes EE, Seiwert T, Blair E, A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFeradeTM Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer (HNC). Abstract Presented at ASCO; 2008
- Stall B, Citrin D, Seidel M, Early Results of a pilot study of intra-tumoral injection of TNFeradeTM biologic concurrent with neo-adjuvant chemoradiation therapy for the treatment of primary and recurrent rectal cancer. Abstract Presented at ASTRO; 2007
- Hernandez J, Mullinax J, Clark W, Survival after pancreaticoduodenectomy is not improved by extending resections to achieve negative margins. Ann Sur 2009;250(1):76-80
- Bates RC, Mercurio AM. Tumor necrosis factor-alpha stimulates the epithelial-to-mesenchymal transition of human colonic organoids. Mol Biol Cell 2003;14:1790-800